Navigation Links
Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors
Date:6/15/2013

use you are removing the target," said lead author Suzanne Wardell, PhD, a research scientist working in McDonnell's lab.

Many investigators had assumed that once breast cancer cells developed resistance to tamoxifen, they would be resistant to all drugs that target the estrogen receptor, McDonnell explained.

"We discovered that the estrogen receptor is still a good target, even after it resistance to tamoxifen has developed," he said.

The investigators tested a variety of breast cancer cell types, including tamoxifen-sensitive cells that are resistant to the drug lapatinib, another targeted therapy that is used to treat patients with advanced breast cancer whose tumors contain the mutant HER2 gene. These cells had previously been shown to reactivate estrogen signaling in order to acquire drug resistance. In this cell type, bazedoxifene also potently inhibited cell growth.

Paradoxically, in bone tissue, bazedoxifene mimics the action of estrogen, helping protect it from destruction. Because bazedoxifene has already undergone safety and efficacy studies as a treatment for osteoporosis, it may be a viable near-term option for patients with advanced breast cancer whose tumors have become resistant to other treatment options, Wardell reported. In clinical trials, the most often reported side effect was hot flashes in the bazedoxifene treatment groups.


'/>"/>

Contact: Rachel Harrison
rachel.harrison@duke.edu
919-419-5069
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. IOF Worldwide Conference of Osteoporosis Patient Societies opens in Helsinki
2. Program announced for the 4th Asia-Pacific Osteoporosis Meeting in Hong Kong
3. Worlds largest meeting dedicated to osteoporosis and osteoarthritis opens in Rome
4. European Guidance for the diagnosis & management of osteoporosis in postmenopausal women
5. Less than 1 month to start of European Congress on Osteoporosis & Osteoarthritis in Rome
6. 4th Asia-Pacific Osteoporosis Meeting to be led by regions leading bone experts
7. European Congress on Osteoporosis and Osteoarthritis
8. Summit of osteoporosis experts from CIS countries issue 5-point call for action
9. IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management
10. Launch of the EU large-scale integrating project BlueGenics to combat osteoporosis
11. Register now for the key osteoporosis meeting in the Asia-Pacific region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... MADISON People get type 2 diabetes. So do cats. ... in the shape of proteins protect some and endanger others. ... it only differs a little bit from species to species," ... mammals that get type 2 diabetes, their amylin proteins aggregate ...
... Energy is making good on the second phase of a plant ... by Dr. Joshua Yuan, Texas A&M AgriLife Research plant pathologist., ... Yuan, who was granted $1.8 million for Phase I by the ... source., The scientist said his research is moving ahead so quickly ...
... the Earth has reached the limits of its biophysical ... and social norms relating to material production and consumption ... functioning of our planet,s life support systems. ... pivotal role to play in this transition. This timely ...
Cached Biology News:New look identifies crucial clumping of diabetes-causing proteins 2Plant fuel project moves to second phase under US Energy Department grant 2
(Date:5/29/2015)... Worth, Texas (PRWEB) May 29, 2015 Translation ... grow. This is for a good reason--if used in a ... wonders for the offering of a business product or service ... which translation can have a positive effect on a company's ... or service that anyone in the world can use, why ...
(Date:5/28/2015)... 2015 Research and ... addition of Jain PharmaBiotech,s new report ... Companies" to their offering. ... report deals with therapeutic drug monitoring, a ... care by monitoring drug levels in the ...
(Date:5/28/2015)... , May 28, 2015 ... ) has announced the addition of ... - Technologies, Markets and Companies"  to ... ,This report describes and evaluates animal ... medicine and pharmaceuticals as well as ...
(Date:5/28/2015)... May 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ... Genetics Market by Products, by Testing services - Global ... The global animal genetics market is estimated to ... at a CAGR of 8-9% during the forecast period ... mainly driven by increasing animal protein consumption, increasing adoption ...
Breaking Biology Technology:Three Ways Translation Can Help Businesses Grow 2Global Therapeutic Drug Monitoring Market 2015-2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2
... ... , ... October 19, 2009 -- Genedata, a leading provider of in silico solutions for pharmaceutical ... Medicine, Academy of Sciences of the Czech Republic, to study the effects of air ...
... Inc., today announced that the U.S. Food and Drug ... for the first 15 monoclonal antibodies in its proprietary ... use by blood donor centers, reference laboratories, and hospitals ... was formed earlier this year to directly commercialize its ...
... 17 UCB today announced data that showed rapid ... fatigue of rheumatoid arthritis (RA) as early as the ... damage (seen at week 24) following treatment with Cimzia® ... to 100 weeks. Cimzia® is approved for the treatment ...
Cached Biology Technology:Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 2Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 3Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 4Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance To Enter U.S. Transfusion Diagnostics Market 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 3UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 4UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 5UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 6UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 7UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 8UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 9UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 10UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 11UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 12